Sparsentan Clinical Trials (2026): 11 Studies for Focal Segmental Glomerulosclerosis & Immunoglobulin A Nephropathy
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
11 Sparsentan clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 7 indications (including Focal Segmental Glomerulosclerosis & Immunoglobulin A Nephropathy) and 1,194 total planned enrollment. 2 Phase 3 Sparsentan trials and 5 Phase 2, 1 Phase 4 are listed. 4 Sparsentan clinical trials are actively recruiting at 17 U.S. sites across 14 states. Most recent activity: NCT07555301 (Dec 2029).
Where to Participate: All Sparsentan Trial Sites in the U.S. (17 sites across 14 states)
Every actively recruiting Sparsentantrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT05003986 | Map |
| DE | Nemours Children's Hospital | Wilmington19803 | NCT05003986 | Map |
| FL | Nicklaus Children's Hospital | Miami33155 | NCT05003986 | Map |
| FL | University of Miami, Leonard M. Miller School of Medicine | Miami33136 | NCT05003986 | Map |
| MI | C.S. Mott Children's Hospital | Ann Arbor48109-5008 | NCT05003986 | Map |
| MN | University of Minnesota, Masonic Children's Hospital | Minneapolis55454 | NCT05003986 | Map |
| MO | Children's Mercy Hospitals and Clinics | Kansas City64108 | NCT05003986 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT05003986 | Map |
| NJ | Jersey Shore University Medical Center | Neptune City07753 | NCT05003986 | Map |
| NY | Cohen Children's Medical Center | New Hyde Park11042 | NCT05003986 | Map |
| NC | University of North Carolina at Chapel Hill | Chapel Hill27599 | NCT05003986 | Map |
| NC | Duke Molecular Physiology Institute | Durham22710 | NCT05003986 | Map |
| OH | Nationwide Children's Hospital | Columbus43205 | NCT05003986 | Map |
| OK | University of Oklahoma Health Sciences Center (OUHSC) | Oklahoma City73104 | NCT05003986 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT05003986 | Map |
| TX | Texas Children's Hospital | Houston77030 | NCT05003986 | Map |
| WA | Seattle Children's Hospital | Seattle98105 | NCT05003986 | Map |
Sparsentan clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | not yet recruiting | Total |
|---|---|---|---|---|---|
| P1 | 1 | 1 | 2 | ||
| P2 | 2 | 1 | 2 | 5 | |
| P3 | 1 | 1 | 2 | ||
| P4 | 1 | 1 | |||
| N/A | 1 | 1 |
Recruiting Sparsentan clinical trials (4)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07555301 | SWIANClinical Experience With Sparsentan in Switzerland in IgA Nephropathy | — | IgA Nephropathy (IgAN) | 50 | Jun 2026 |
| NCT07224776 | Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria | P1 | Proteinuric Renal Disease | 20 | Jun 2026 |
| NCT04663204 | SPARTANA Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy | P2 | Immunoglobulin A Nephropathy | 24 | Dec 2020 |
| NCT05003986 | EPPIKStudy of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | P2 | Focal Segmental Glomerulosclerosis | 67 | Aug 2021 |
Sparsentan clinical trials by indication
Immunoglobulin A Nephropathy (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04663204 | SPARTAN | P2 | recruiting | A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy |
| NCT03762850 | PROTECT | P3 | active not recruiting | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy |
| NCT05856760 | SPARTACUS | P2 | completed | A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN |
Focal Segmental Glomerulosclerosis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05003986 | EPPIK | P2 | recruiting | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases |
| NCT03493685 | DUPLEX | P3 | completed | Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) |
| NCT01613118 | DUET | P2 | completed | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis |
IgA Nephropathy (IgAN) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07555301 | SWIAN | N/A | not yet recruiting | Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy |
Proteinuric Renal Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07224776 | — | P1 | not yet recruiting | Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria |
Proteinuria (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07219121 | SPARX | P4 | active not recruiting | Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis |
ANCA Associated Vasculitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05630612 | SPARVASC | P2 | active not recruiting | ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) |
Healthy Subjects (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05562362 | — | P1 | completed | Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension |
Sparsentan pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SPARX | NCT07219121 | P4 | active not recruiting | Proteinuria | 20 | — |
| PROTECT | NCT03762850 | P3 | active not recruiting | Immunoglobulin A Nephropathy | 406 | PMID 38299639 |
| DUPLEX | NCT03493685 | P3 | completed | Focal Segmental Glomerulosclerosis | 371 | PMID 41433094 |
| SPARTAN | NCT04663204 | P2 | recruiting | Immunoglobulin A Nephropathy | 24 | — |
| SPARVASC | NCT05630612 | P2 | active not recruiting | ANCA Associated Vasculitis | 32 | PMID 35998848 |
| EPPIK | NCT05003986 | P2 | recruiting | Focal Segmental Glomerulosclerosis | 67 | PMID 40938675 |
| SPARTACUS | NCT05856760 | P2 | completed | Immunoglobulin A Nephropathy | 48 | — |
| DUET | NCT01613118 | P2 | completed | Focal Segmental Glomerulosclerosis | 109 | PMID 30361325 |
All Sparsentan trials (11)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07555301 | SWIAN | Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy | — | not yet recruiting | 50 | Waid City Hospital, Zurich | Jun 2026 |
| NCT07224776 | Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria | P1 | not yet recruiting | 20 | Brigham and Women's Hospital | Jun 2026 | |
| NCT04663204 | SPARTAN | A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy | P2 | recruiting | 24 | University of Leicester | Dec 2020 |
| NCT05630612 | SPARVASC | ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) | P2 | active not recruiting | 32 | University of Edinburgh | Dec 2022 |
| NCT07219121 | SPARX | Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis | P4 | active not recruiting | 20 | Travere Therapeutics, Inc. | Oct 2025 |
| NCT05003986 | EPPIK | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | P2 | recruiting | 67 | Travere Therapeutics, Inc. | Aug 2021 |
| NCT03762850 | PROTECT | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy | P3 | active not recruiting | 406 | Travere Therapeutics, Inc. | Dec 2018 |
| NCT03493685 | DUPLEX | Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) | P3 | completed | 371 | Travere Therapeutics, Inc. | Apr 2018 |
| NCT05856760 | SPARTACUS | A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN | P2 | completed | 48 | Travere Therapeutics, Inc. | May 2023 |
| NCT01613118 | DUET | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis | P2 | completed | 109 | Travere Therapeutics, Inc. | Mar 2014 |
| NCT05562362 | Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension | P1 | completed | 47 | Travere Therapeutics, Inc. | Jun 2020 |
Sparsentan clinical trials: frequently asked questions
- How many Sparsentan clinical trials are there?
- 11 Sparsentan clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 4 are marked completed.
- Are Sparsentan clinical trials recruiting in 2026?
- Yes — 2 Sparsentan trials are actively recruiting in 2026, with 17 U.S. sites across 14 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Sparsentan being studied for?
- Sparsentan is being studied for Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy, Proteinuria, Kidney Diseases, Glomerulonephritis and 15 more. The trials are grouped by indication on this page.
- What phase is Sparsentan in?
- Sparsentan clinical trials span 1 Phase 4, 2 Phase 3, 5 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Sparsentan clinical trials?
- The lead sponsor across the most Sparsentan trials is Travere Therapeutics, Inc., with 4 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Sparsentanas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: